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The possibility to utilize nanotechnology for drug develop-
ment has led to widespread interest and funding opportunities.
The public perception of the field of nanoscale science orig-
inally referred to technologies dealing with nanomechanics,
nanomaterials, nanooptics and nanoelectronics, but increas-
ingly anticipates progress in nanomedicine. Today’s molecu-
lar imaging possibilities are ideal for visualizing the pharma-
cokinetics of the effectors used in new treatment strategies
such as gene therapy [1] and therapeutic vaccination [2]. With
the possibility to visualize and the salient, concomitant treat-
ment, nuclear medicine has the greatest potential for use in the
development of innovative treatment strategies. Consequent-
ly, the eventual applications of nanosized tracers are of the
greatest interest for our discipline.
Nanoparticles can be strictly defined as microscopic particles
with at least one dimension less than 100 nm. Nanoparticles
used for pharmaceutical applications are normally above the
renal exclusion limit (approximately 50 kDa) but small enough
to pass through all blood capillaries. Together with the compo-
nents required to provide specific functions (Fig. 1), targeted
nanoparticles reach a few hundred nanometres in size (the size
of the smallest bacteria), intermediate between large proteins
(e.g. antibodies with a hydrodynamic radius of approximately
15 nm) and microspheres (particles in the micrometre range,
typically 10 to 200 µm). A distinction has to be made
between microspheres and nanoparticles. Microspheres have
gained increasing importance for two reasons. First, they
can be used in the embolization of fine capillaries.
Following locoregional administration into the blood vessels
supplying a tumour, microspheres accumulate in the tumour
tissue. Radioembolization using 90Y-labelled microspheres
such as SIR-Spheres® and TheraSpheres® can be used for
the treatment of patients with unresectable hepatocellular car-
cinoma [3]. Second, they can be used in the location of the
sentinel lymph node in the management of patients with early
breast cancer. The sentinel node extracts radiolabelled parti-
cles from the lymph and can be intraoperatively detected using
a hand-held gamma probe [4].
At first glance nanoparticles have the potential to greatly
extend the current repertoire of therapeutic applications by
providing the means to transport various cargos. In nuclear
medicine applications this includes a choice of radionuclides
for either diagnostic or therapeutic applications. Targeting of
the particles can be achieved by modifiers readily chosen from
the large repertoire of targeting molecules, such as peptides and
antibodies. A large variety of nanoparticle delivery systems
such as polymeric nanoparticles, liposomes, dendrimers,
polymerosomes and inorganic particles have been described.
The most prominent compounds are encapsulated cytotoxic
drugs, such as DOXIL®, PEGylated liposomes containing the
topoisomerase inhibitor doxorubicin. However, PEGylated li-
posomal doxorubicin is still used far less than free doxorubicin
as it causes dose-limiting side effects, differing from those of
doxorubicin, notably palmoplantar erythrodysaesthesia (hand-
foot syndrome) [5].
Unfortunately, there are serious shortcomings in the clini-
cal application of nanoparticles. Nanoparticles have a propen-
sity to adsorb serum proteins such as opsonin causing their
marking out for immediate destruction by the immune system.
Biodistribution studies of unmodified nanoparticles have
shown their rapid accumulation in the liver, spleen and bone
marrow (reticuloendothelial system). Therefore, a major pro-
portion of the particles are trapped by these normal organs and
are not available for the target, i.e. tumour, tissue. While this
problem can be avoided by coating with polyethylene glycol
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[6], it should be born in mind that any coating chosen to
suppress recognition by the immune system is inevitably
associated with interference with specific binding.
The lack of specificity of a naked nanoparticle has been
approached by coupling the nanoparticles with targeting mol-
ecules such as antibodies, receptor affine peptides, folate
receptor ligands or bisphosphonates on their surface [7].
However, the number of potential targeting molecules is lim-
ited to molecules that are not influenced by conjugation to
particles. The strategy to direct the accumulation to a specific
target whilst limiting nonspecific accumulation faces two
problems: (1) the affinity of the targeting molecule is
influenced by the large particle to which it is attached, and
(2) the biodistribution of the small molecule/peptide/antibody
is dominated by the large particle. All modifications required
to facilitate targeting and biocompatibility, however, increase
the size of the particle, and such increase is detrimental to the
quality of the pharmaceutical which generally decreases with
increasing size [8].
It is possible that nanoparticles can be transported through
the interendothelial junctions which are enlarged in tumours.
However, the likelihood that large constructs can penetrate
deeply into tissue, and make their way back from sites where
no specific interaction takes place can be estimated from a
comparison with oxygen. The permanent oxygen shortage in
large solid tumours reveals the enormous diffusion barrier to
be overcome. The diffusion constants of O2 and macromole-
cules differ by many orders of magnitude. Tumours show a
poorly organized vascular architecture and compression of
blood and lymphatic vessels by cancer cells. In addition to
hypoxia, this creates increased interstitial fluid pressure which
can slow down the movement of molecules within the tumour
and limits the delivery of drugs to cells located far from
functioning blood vessels [9]. Mobility is therefore a main
factor defining the performance of a tracer in an organism
expressing a target at a defined specificity. Antibodies are an
instructive example of this. Their large size counteracts their
excellent properties and binding affinity. However, antibodies
have the advantage of outstanding biocompatibility and there-
fore attain exceptional circulation times. This increases the
probability of constructive interaction and thus compensates
for their lower mobility.
Most discussions regarding the interaction of targeted mol-
ecules neglect the fact that the specific interaction will take
place at the surface of the tumour cells and consequently far
away from the bloodstream (Fig. 2). In many cases the pro-
liferation of tumour cells leads to a cellular population that is
at a considerable distance (>100 µm) from vessels where the
microenvironment is dictated by hypoxia and reduced pH.
This area also shows reduced vascular density. As a function
of their size, all drugs suffer from a steep concentration
gradient which decreases with increasing distance from the
surrounding blood vessels [10].As a logical result clinical
application of nanoparticles should be considered impossible.
It is argued that nanocarriers can penetrate the tumour vascu-
lature through its leaky endothelium and, in this way, accu-
mulate in solid tumours; this is referred to as the enhanced
permeation and retention (EPR) effect (Fig. 3). A simple
calculation reveals that this effect cannot result in the uptake
of significant amounts of a drug. For example, an injection of
a hypothetical dose of 1 g of articles would compete for uptake
with approximately 300 g of serum protein. An assumed
capillary volume of 1 ml in a tumour of 10 cm3 will accom-
modate a total of approximately 50 mg of macromolecules,
corresponding to 0.16 mg of particles. It is therefore clear why
the EPR effect can only be demonstrated in animal models
Fig. 1 Schematic illustration of the structure of a nanoparticle comprising
the components presumed to enable targeted drug delivery
Fig. 2 Schematic illustration of the extravasation and distance to be
bridged by targeted particles. Passage through the endothelial cell layer
and migration over distances of the order of 100 µm are required to reach
tissue in which the particles might be retained by specific interaction
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with artificial tumours grown within days to reach a signifi-
cant fraction of the whole animal weight [11], and not in
clinical situations that physicians are confronted with in tu-
mours in patients.
The main idea behind most nanosized drug platforms relies
on their potential to encapsulate the cargo and thereby shield it
during transport to the site of action, and preventing its action
prior to arrival. Generally, this does not apply to radiophar-
maceuticals as their effect—the radiation—cannot be shielded
in the particle.
Finally, it has to be born in mind that the defined produc-
tion of nanoparticles that fulfil the requirements for clinical
use is extremely demanding. At present, it is already difficult
to meet the regulatory requirements for small molecules. It is
therefore hard to know whether it would be possible to con-
sistently produce such complex products which vary in size,
degree of loading, core composition, the number and site of
modifications attached and many other issues such as the
functionality of the labelling sites and the targeting moieties.
In conclusion, the size of nanoparticles will prevent their
use as drugs. Attempts should therefore be focused on
small molecules that possess the mobility required to exploit
their specificity.
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Fig. 3 Schematic illustration of extravasation at sites of disturbed micro-
vasculature, the basis for the enhanced permeation and retention effect
considered to be active in the selective uptake of nanoparticles. It is
reasonable to consider that all macromolecules compete in this process,
with a substantial disadvantage for nanoparticles because of their number
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